Plasma-Based Genotyping Pays Off in NSCLC.
A recent study showed that plasma-based genotyping of circulating tumor DNA from patients with metastatic non-small cell lung cancer detected clinically relevant targetable driver and resistance mutations in roughly one third of cases, whether used alone or in combination with sequencing data from tumor tissue. This means that liquid biopsies are a valid clinical option for many patients. In addition, more than 85% of patients who received targeted treatment based on the liquid biopsy findings experienced a complete or partial response or stable disease.